Adoptive Cell Immunotherapy for Cancer

We are dedicated to research of cellular therapy for cancer with a focus on Adoptive T cell Transfer. The goal of our work is to produce antigen-specific T cells with desired functions and to produce them under conditions that would allow their use in clinics. The desired function of these T cells for cancer therapy should be their ability to eliminate cancer cells through recognition of multiple tumor-associated antigens (TAAs), migrate into tumors, and have the phenotype that would ensure their persistence after their transfer to the patient. Our studies are focused on prostate cancer and renal cell carcinoma.

Principal Investigator

Daniel Smrž, Ph.D.



Ph.D. Students

Pavla Táborská, Ing.

Dmitry Stakheev, M.D., Ph.D.

Zuzana Střížová, M.D., Ph.D.

Undergraduate Students

Hana Svobodová, B.Sc.

Senior Scientists/Clinicians

Michal Podrazil, M.D., Ph.D.

prof. Jiřina Bartůňková, M.D., Ph.D., MBA

Current Grants

The Grant Agency of the Charles University, Czech Republic, No. 364218, Isolation, characterization and expansion of subsets of tumor-infiltrating lymphocytes of kidney cancer for the development of adoptive cell immunotherapy, 2018–2020

Charles University, No. PRIMUS/MED/12, Preparation of cytotoxic polyclonal T-cells for adoptive cellular immunotherapy of cancer, 2017–2019

  • Ministry of Health of the Czech Republic, project AZV, No. 16-28135A, Preparation of polyclonal cancer-specific T-cells for adoptive cellular immunotherapy of prostate cancer, 2016–2019
Created: 23. 5. 2019 / Modified: 21. 9. 2020 / Responsible person: RNDr. Jan Lašťovička, CSc.